Intravenous pamidronate treatment of children under 36 months of age with osteogenesis imperfecta

Linda DiMeglio, L. Ford, C. McClintock, Munro Peacock

Research output: Contribution to journalArticle

63 Citations (Scopus)

Abstract

Bone mineral density (BMD) and fracture rates in children with osteogenesis imperfecta (OI) have been shown to improve with bisphosphonate therapy. There are limited data available on the efficacy of this therapy in children with OI under the age of 3 years. To examine this, we instituted a prospective clinical trial of intravenous bisphosphonate to study safety, feasibility, and efficacy of this therapy. Nine infants and young children with osteogenesis imperfecta (age range 1-35 months) were treated with intravenous pamidronate. Six had type II OI, two had type I, and one had type IV. Pamidronate was administered in cycles of 3 consecutive days. The total duration of therapy ranged from 11 to 29 months (mean 17 months). During treatment, the mean annualized percent change in total body areal BMD was 25% (range 11-40%). Pamidronate therapy resulted in sustained and significant decreases in serum calcium and bone-specific alkaline phosphatase and in urine calcium/creatinine and NTX/creatinine. Fracture rate in the group decreased from 80 fractures in 111 months before treatment to 25 fractures in 152 months after treatment (P < 0.01). Linear growth and weight gain were maintained. Other than fevers in several infants following the initial dose of intravenous bisphosphonate no adverse effects of therapy were noted. Our data support that intravenous pamidronate therapy is safe, increases BMD, and reduces fracture rates in very young children with OI. Currently, it would seem to be the best available treatment for these children.

Original languageEnglish
Pages (from-to)1038-1045
Number of pages8
JournalBone
Volume35
Issue number5
DOIs
StatePublished - Nov 2004

Fingerprint

pamidronate
Osteogenesis Imperfecta
Diphosphonates
Therapeutics
Bone Density
Creatinine
Calcium

Keywords

  • Bisphosphonate
  • Bone
  • Bone density
  • Children
  • Fracture
  • Pediatrics

ASJC Scopus subject areas

  • Physiology
  • Hematology

Cite this

Intravenous pamidronate treatment of children under 36 months of age with osteogenesis imperfecta. / DiMeglio, Linda; Ford, L.; McClintock, C.; Peacock, Munro.

In: Bone, Vol. 35, No. 5, 11.2004, p. 1038-1045.

Research output: Contribution to journalArticle

@article{921abc411f184a979d63d7b3939d1dff,
title = "Intravenous pamidronate treatment of children under 36 months of age with osteogenesis imperfecta",
abstract = "Bone mineral density (BMD) and fracture rates in children with osteogenesis imperfecta (OI) have been shown to improve with bisphosphonate therapy. There are limited data available on the efficacy of this therapy in children with OI under the age of 3 years. To examine this, we instituted a prospective clinical trial of intravenous bisphosphonate to study safety, feasibility, and efficacy of this therapy. Nine infants and young children with osteogenesis imperfecta (age range 1-35 months) were treated with intravenous pamidronate. Six had type II OI, two had type I, and one had type IV. Pamidronate was administered in cycles of 3 consecutive days. The total duration of therapy ranged from 11 to 29 months (mean 17 months). During treatment, the mean annualized percent change in total body areal BMD was 25{\%} (range 11-40{\%}). Pamidronate therapy resulted in sustained and significant decreases in serum calcium and bone-specific alkaline phosphatase and in urine calcium/creatinine and NTX/creatinine. Fracture rate in the group decreased from 80 fractures in 111 months before treatment to 25 fractures in 152 months after treatment (P < 0.01). Linear growth and weight gain were maintained. Other than fevers in several infants following the initial dose of intravenous bisphosphonate no adverse effects of therapy were noted. Our data support that intravenous pamidronate therapy is safe, increases BMD, and reduces fracture rates in very young children with OI. Currently, it would seem to be the best available treatment for these children.",
keywords = "Bisphosphonate, Bone, Bone density, Children, Fracture, Pediatrics",
author = "Linda DiMeglio and L. Ford and C. McClintock and Munro Peacock",
year = "2004",
month = "11",
doi = "10.1016/j.bone.2004.07.003",
language = "English",
volume = "35",
pages = "1038--1045",
journal = "Bone",
issn = "8756-3282",
publisher = "Elsevier Inc.",
number = "5",

}

TY - JOUR

T1 - Intravenous pamidronate treatment of children under 36 months of age with osteogenesis imperfecta

AU - DiMeglio, Linda

AU - Ford, L.

AU - McClintock, C.

AU - Peacock, Munro

PY - 2004/11

Y1 - 2004/11

N2 - Bone mineral density (BMD) and fracture rates in children with osteogenesis imperfecta (OI) have been shown to improve with bisphosphonate therapy. There are limited data available on the efficacy of this therapy in children with OI under the age of 3 years. To examine this, we instituted a prospective clinical trial of intravenous bisphosphonate to study safety, feasibility, and efficacy of this therapy. Nine infants and young children with osteogenesis imperfecta (age range 1-35 months) were treated with intravenous pamidronate. Six had type II OI, two had type I, and one had type IV. Pamidronate was administered in cycles of 3 consecutive days. The total duration of therapy ranged from 11 to 29 months (mean 17 months). During treatment, the mean annualized percent change in total body areal BMD was 25% (range 11-40%). Pamidronate therapy resulted in sustained and significant decreases in serum calcium and bone-specific alkaline phosphatase and in urine calcium/creatinine and NTX/creatinine. Fracture rate in the group decreased from 80 fractures in 111 months before treatment to 25 fractures in 152 months after treatment (P < 0.01). Linear growth and weight gain were maintained. Other than fevers in several infants following the initial dose of intravenous bisphosphonate no adverse effects of therapy were noted. Our data support that intravenous pamidronate therapy is safe, increases BMD, and reduces fracture rates in very young children with OI. Currently, it would seem to be the best available treatment for these children.

AB - Bone mineral density (BMD) and fracture rates in children with osteogenesis imperfecta (OI) have been shown to improve with bisphosphonate therapy. There are limited data available on the efficacy of this therapy in children with OI under the age of 3 years. To examine this, we instituted a prospective clinical trial of intravenous bisphosphonate to study safety, feasibility, and efficacy of this therapy. Nine infants and young children with osteogenesis imperfecta (age range 1-35 months) were treated with intravenous pamidronate. Six had type II OI, two had type I, and one had type IV. Pamidronate was administered in cycles of 3 consecutive days. The total duration of therapy ranged from 11 to 29 months (mean 17 months). During treatment, the mean annualized percent change in total body areal BMD was 25% (range 11-40%). Pamidronate therapy resulted in sustained and significant decreases in serum calcium and bone-specific alkaline phosphatase and in urine calcium/creatinine and NTX/creatinine. Fracture rate in the group decreased from 80 fractures in 111 months before treatment to 25 fractures in 152 months after treatment (P < 0.01). Linear growth and weight gain were maintained. Other than fevers in several infants following the initial dose of intravenous bisphosphonate no adverse effects of therapy were noted. Our data support that intravenous pamidronate therapy is safe, increases BMD, and reduces fracture rates in very young children with OI. Currently, it would seem to be the best available treatment for these children.

KW - Bisphosphonate

KW - Bone

KW - Bone density

KW - Children

KW - Fracture

KW - Pediatrics

UR - http://www.scopus.com/inward/record.url?scp=8444229279&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=8444229279&partnerID=8YFLogxK

U2 - 10.1016/j.bone.2004.07.003

DO - 10.1016/j.bone.2004.07.003

M3 - Article

VL - 35

SP - 1038

EP - 1045

JO - Bone

JF - Bone

SN - 8756-3282

IS - 5

ER -